Question 55

Pharmacies must report the theft or significant loss of Carisoprodol to the DEA.

Carisoprodol is classified as a controlled substance, which mandates that any theft or significant loss must be reported to the Drug Enforcement Administration (DEA) as part of regulatory compliance.

A) Carbamazepine

Carbamazepine is not classified as a controlled substance under the federal law; therefore, pharmacies are not required to report its theft or significant loss to the DEA. While it may be subject to other regulations, it does not fall under the same reporting requirements as controlled substances.

B) Carbidopa

Carbidopa is not a controlled substance and does not require reporting to the DEA in the event of theft or significant loss. This medication is used primarily in conjunction with levodopa for the treatment of Parkinson’s disease and is not subject to the same stringent regulations as controlled substances.

C) Carvedilol

Carvedilol is also not classified as a controlled substance, meaning that pharmacies do not need to notify the DEA about its theft or significant loss. This medication is primarily used for treating heart failure and hypertension, and it does not have the same potential for abuse or dependency as controlled substances do.

D) Carisoprodol

Carisoprodol is classified as a Schedule IV controlled substance, which requires pharmacies to report any theft or significant loss to the DEA. This classification is due to its potential for abuse and dependency, making it necessary to adhere to strict reporting regulations.

Conclusion

Carisoprodol is the only option listed that is a controlled substance, necessitating that any theft or significant loss be reported to the DEA. The other options, Carbamazepine, Carbidopa, and Carvedilol, do not fall under the controlled substances category and therefore do not require such reporting. This distinction underscores the importance of compliance with regulations concerning controlled substances in pharmacy practice.